Brought to you by 
Athena in 10-year US marketing agreement for Lilly's Permax
08 May 2002
Executive Summary
Athena Neurosciences has acquired exclusive US marketing rights for 10 years to Permax (pergolide mesylate) for Parkinson's disease from Eli Lilly.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Athena in 10-year US marketing agreement for Lilly's Permax
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice